Research and Markets (http://www.researchandmarkets.com/research/16cc0f/morocco_pharmaceut) has announced the addition of the "Morocco Pharmaceuticals and Healthcare Report Q4 2009" report to their offering.
This Morocco Pharmaceuticals and Healthcare Report provides industry professionals and strategists, corporate analysts, pharmaceutical associations, government departments and regulatory bodies with independent forecasts and competitive intelligence on Morocco's pharmaceuticals and healthcare industry
The publisher expects the drug market in Morocco to increase in value from US$1.38bn in 2008 to US$1.88bn in 2013, representing a compound annual growth rate (CAGR) of 5.5% in US dollar terms. The strong development of the sector is linked to an expanding economy and a growing middle class, both of which will underpin increased drug spending. The global financial crisis has not hit Morocco with the same force experienced in other countries in the world, which bodes well for pharmaceutical sector, while stable levels of inflation mean that real growth rates will be over 7% in both 2008 and 2009. The main risk to this scenario revolves around whether current levels of health expenditure are sustainable. With life expectancy growing in Morocco, the number of elderly people dependent on social security is increasing and could reach 5.8mn by 2030. Meanwhile, high drug prices and a lack of generic penetration are having an inflationary impact on health spending. However, BMI believes that while the economy continues to expand rapidly, many of these problems will remain in the background. Despite the global economic downturn, Morocco's High Planning Commission (HCP) has said that the country is likely to register economic growth of 5.3% in 2009. Although the publisher feels these figures for economic growth are quite optimistic, BMI maintains a positive forecast of 2.4% real GDP growth in Morocco in 2009.